OCT 18, 2019 11:00 AM PDT

AcroMetrix BCR-ABL External Molecular Panel: An Accurate Testing Method for Chronic Myeloid Leukemia

WRITTEN BY: Nupur Srivastava

To support the validation and verification of new assays and to challenge the existing assays in oncology testing, Thermo Fisher Scientific launches Thermo Scientific Acrometrix BCR-ABL Panel. The product provides innovative standards for analytical BCR-ABL test methods in chronic myeloid leukemia (CML) disease. 

Chronic myeloid leukemia (CML) is a cancer of the blood-forming cells, called myeloid cells, found in the bone marrow. In CML, the bone marrow produces more white blood cells that usually are involved in fighting infection. 

BCR-ABL1 is a gene sequence that confirms the diagnosis of Chronic Myeloid Leukemia (CML), persistent bone marrow cancer. The detected gene is present in abnormal chromosome 22 of humans. In CML, part of chromosome 9 breaks off and bonds to a section of chromosome 22, forming the fusion chromosome. The abnormal BCR-ABL1 gene encodes an abnormal protein (tyrosine kinase) that is responsible for the development of CML.

Different testing types (cytogenetics, fluorescence in-situ hybridization, genetic molecular) are available to diagnose CML. The Acrometrix BCR-ABL external control panel is launched to quantitate BCR-ABL RNA accurately. The first of its kind, the product is useful to make a critical, timely, patient treatment decisions. The test product intends for research-use-only. The testing method can monitor assay performance at every clinical stage due to its expanded dynamic range.

"The Acrometrix BCR-ABL Panel is the first full-process molecular control for challenging validated BCR-ABL assay performance, providing researchers and laboratorians with greater confidence utilizing a highly characterized product," said Fernando Beils, vice president and general manager of Clinical Diagnostics for Thermo Fisher. "Additionally, this new molecular control panel is traceable to the new World Health Organization (WHO) standards for genetic reference panels for the quantitation of BCR-ABL. This provides assurance to laboratory staff that there is accuracy in the measurement of their assay results."

Sources: AmericanCancerSociety, ThermoFisherScientific

About the Author
You May Also Like
OCT 29, 2020
Clinical & Molecular DX
More Frequent Trips to the Pediatrician Linked to a Future Autism Diagnosis
OCT 29, 2020
More Frequent Trips to the Pediatrician Linked to a Future Autism Diagnosis
 
DEC 10, 2020
Clinical & Molecular DX
Gut Feeling: Microbiome Reveals Toxic Chemical Exposure in Kids
DEC 10, 2020
Gut Feeling: Microbiome Reveals Toxic Chemical Exposure in Kids
A study by Duke University researchers has revealed that children’s gut microbiomes hold clues as to their possibl ...
DEC 15, 2020
Clinical & Molecular DX
Who Should Get the COVID Vaccine First?
DEC 15, 2020
Who Should Get the COVID Vaccine First?
Drug developers’ frantic hunt for vaccines against SARS-CoV-2 has finally begun to bear fruit, with several vaccin ...
JAN 07, 2021
Cardiology
Climbing Some Stairs is a Good Way to Check Heart Health
JAN 07, 2021
Climbing Some Stairs is a Good Way to Check Heart Health
If you can climb four flights in under a minute, your heart is probably in good shape, according to new work presented a ...
JAN 08, 2021
Neuroscience
Can We Identify Alzheimer's from Routine Eye Exams?
JAN 08, 2021
Can We Identify Alzheimer's from Routine Eye Exams?
As people with diabetes age, they are more likely than those without the condition to develop cognitive disorders such a ...
JAN 27, 2021
Clinical & Molecular DX
No Pain, All the Diagnostic Gain
JAN 27, 2021
No Pain, All the Diagnostic Gain
A recent study published in Nature Biomedical Engineering describes new microneedle patch technology that takes the &ldq ...
Loading Comments...